Thymopoietin dosing & administration
Thymic hormone that supports T-cell development and immune function, with the active fragment thymopentin (TP-5) used in clinical research
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Dosing
How much do I take?
Subcutaneous injection: A small injection into the fatty layer just under the skin — the same way insulin is given.
Bioavailability High — most of the dose reaches your bloodstream, just more gradually than an IV.
50 mg (as the active thymopentin/TP-5 pentapeptide)
Frequency
Three times weekly
Duration
6 weeks to several months
The full-length thymopoietin hormone is not dosed directly in humans; its immune activity is delivered clinically through its active pentapeptide fragment thymopentin (TP-5), studied at 50 mg SC three times weekly [5].
Timing
Best time to take
Morning or early afternoon, allowing at least 24 hours between doses
With food?
Can be taken with or without food
If stacking
If combining with indomethacin, space dosing by at least 2-4 hours. Avoid timing with live vaccines or high-dose corticosteroids.
Adjusting your dose
Increase if
- No adverse reactions after first 2 weeks
- Initial immune markers show no improvement
- Medically supervised and treating specific condition
Decrease if
- Injection site irritation becomes severe
- Signs of neuromuscular weakness appear
- Fever or systemic symptoms develop
- Autoimmune symptoms worsen
Signs of right dose
- Improved T-cell counts
- Reduced infection frequency
- Better energy and recovery
- Improved lymphocyte profiles
Administration
How do I use it?
Reconstitution
What you need
Injection
Route
Subcutaneous injection (primary method); can be intravenous under medical supervision
Best sites
Storage
Before reconstitution
Keep sealed vial in original container at 2-8°C (refrigerator). Protect from light and moisture. Do not freeze. Keep away from heat sources.
After reconstitution
Store reconstituted solution in sealed vial at 2-8°C. Keep needle-free cap on when not in use. Use within 24 hours of reconstitution.
Signs of degradation — discard the vial
Sample daily schedule
Morning
50 mg injection
Site: Alternate between upper arm and abdomen
Monday, Wednesday, Friday schedule for standard 3x/week dosing
Morning
50 mg injection
Site: Alternate between upper arm and abdomen
For every-other-day schedule, inject on Monday, Wednesday, Friday, Sunday
Any time of day
As prescribed injection
Site: Medical-supervised injection
Intravenous administration only under medical/clinical supervision
Safety
Is it safe?
Side effects
Commonly reported: Injection site redness or swelling, Mild fever, Transient lymphocytosis
Less common: Mild to moderate fatigue, Temporary headaches, Joint or muscle aches
Stop and seek help if
- Severe neuromuscular weakness or myasthenia-like symptoms appear
- Severe allergic reactions occur
- Signs of autoimmune disease flare up
- Persistent fever over 101.5°F
- Severe injection site reactions with spreading redness or warmth
- Pregnancy is discovered
- Diagnosed with myasthenia gravis or neuromuscular disorder
This information is educational. Always consult with a healthcare provider before starting, stopping, or changing thymopoietin use. Emergency symptoms require immediate medical attention.
Published research
What the studies show
Goldstein G · 1975
This study investigated the properties and effects of Thymopoietin, contributing to our understanding of its mechanism of action and potential therapeutic applications.
Rajnavölgyi E, Kulics J, Szilágyvári M, et al. · 1986
This study investigated the properties and effects of Thymopoietin, contributing to our understanding of its mechanism of action and potential therapeutic applications.
Sempowski GD, et al. · 2018
This study investigated the properties and effects of Thymopoietin, contributing to our understanding of its mechanism of action and potential therapeutic applications.
Schulof RS · 1985
This study investigated the properties and effects of Thymopoietin, contributing to our understanding of its mechanism of action and potential therapeutic applications.
Goldstein G, et al. · 1995
Head to head
Thymopoietin compared
Want the full picture?
The complete Thymopoietin research profile: mechanism of action, clinical studies, effectiveness timeline, and FAQ.